Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Memorial Sloan Kettering Cancer Center.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT01864109
First received: May 23, 2013
Last updated: January 16, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2019
  Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)